deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02628535

Safety Study of MGD009 in B7-H3-expressing Tumors

Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms

Sponsor: MacroGenics

Conditions Bladder Cancer Breast Cancer Clear Cell Renal Cell Carcinoma Colon Cancer Melanoma Mesothelioma Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer Soft Tissue Sarcoma Squamous Cell Carcinoma of the Head and Neck Thyroid Cancer
Interventions MGD009
Updated 19 times since 2017 Last updated: Feb 4, 2022 Started: Sep 30, 2015 Primary completion: Nov 25, 2019 Completion: Nov 25, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision (not for safety reasons)

Other terminated trials from MacroGenics

See all terminations from MacroGenics

Other Bladder Cancer trials with similar outcome

Browse all Bladder Cancer trials

A PHASE1 clinical study on Bladder Cancer and Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by MacroGenics and has accumulated 19 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Apr 2020 · 7 months · monthly snapshot~Apr 2020 – ~Sep 2020 · 5 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Mar 2022 · 12 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Mar 2022 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Mar 2021 — Mar 2022 [monthly]

    Terminated PHASE1

▶ Show 14 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE1

  2. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE1

  3. Apr 2020 — Sep 2020 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Sep 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Apr 2019 — Sep 2019 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  6. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE1

  7. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  9. Sep 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  11. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  13. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • MacroGenics
Data source: MacroGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Camperdown, Australia , Dallas, United States , Darlinghurst, Australia , Fairfax, United States , Heidelberg, Australia , Huntersville, United States , Los Angeles, United States , Nashville, United States , Nedlands, Australia and 8 more locations